Fatigue Syndrome, Chronic Clinical Trial
Official title:
Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer
The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.
The overall goal of this proposal is to evaluate the efficacy of testosterone replacement therapy in improving fatigue and other outcomes such as sexual function, quality of life, body composition, muscle strength and physical activity in a double-blind, randomized, placebo-controlled trial in young cancer survivors who report fatigue and have testosterone deficiency. Fatigue is one of the most prevalent and debilitating symptoms in men with cancer affecting 70-100% of patients irrespective of their age. Cancer-related fatigue is experienced by patients not only during active cancer treatment, but is also highly prevalent in cancer survivors who exhibit persistent fatigue months to years after the end of their treatment with the highest prevalence being in recipients of chemotherapy and/or radiation therapy. In addition to fatigue, sexual dysfunction is also highly prevalent in male cancer survivors. Male cancer survivors also have increased fat mass and decreased lean body mass, a phenotype that predisposes them to reduced muscle strength. This phenotype of fatigue, sexual dysfunction and adverse body composition is commonly encountered in non-cancer patient populations with testosterone deficiency, a condition which is also highly prevalent (50-90%) in cancer survivors. Pivotal trials of testosterone replacement therapy in non-cancer patient populations have shown an improvement in fatigue, sexual function and body composition in men randomized to testosterone compared with placebo. However, the efficacy of testosterone replacement therapy on cancer-related fatigue has not been studied. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04467697 -
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
Completed |
NCT04326673 -
Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
|
||
Completed |
NCT03203681 -
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
|
Phase 4 | |
Completed |
NCT01904734 -
Clomid in Men With Low Testosterone With and Without Prior Treatment
|
Phase 2 | |
Completed |
NCT00398580 -
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00400335 -
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
|
Phase 1 | |
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT03282682 -
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
|
N/A | |
Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
Completed |
NCT03747003 -
Gonadal Function in Young to Middle Aged HIV-infected Men
|
||
Withdrawn |
NCT03176537 -
Periodontal Profile of Hypogonadic Men
|
Phase 4 | |
Completed |
NCT03541395 -
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
|
N/A | |
Recruiting |
NCT05249634 -
Testosterone Treatment in Men With Chronic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT05773183 -
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
|
||
Withdrawn |
NCT04717362 -
The Effects of Natesto For Treatment Of Hypogonadism
|
Early Phase 1 | |
Completed |
NCT05806723 -
Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men
|
Phase 4 | |
Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
Not yet recruiting |
NCT06312761 -
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
|
Phase 1/Phase 2 | |
Recruiting |
NCT05381831 -
Natesto Spermatogenesis Reboot
|
Phase 4 |